MIRD-237 is based on a proprietary chelator system conjugated to a targeting moiety specific for certain types of cancer cells. The compound is labeled with Actinium-225 (^225Ac), an alpha-emitting radionuclide known for its high linear energy transfer (LET) and short half-life of approximately 10 days. The targeting moiety is designed to selectively bind to overexpressed receptors on the surface of specific cancer cells, ensuring the delivery of a lethal dose of radiation directly to the tumor site while minimizing exposure to healthy tissues.
The MIRD-237 is a next-generation radioisotope thermoelectric generator (RTG), building on the success of previous RTG designs, such as the General-Purpose Heat Source (GPHS) RTG and the Radioisotope Thermoelectric Generator (RTG) used on the Cassini-Huygens mission. The MIRD-237 was developed by the Department of Energy's (DOE) Office of Nuclear Energy, in collaboration with NASA and private industry partners. The goal of the MIRD-237 project was to create a more efficient, compact, and versatile RTG that could meet the diverse power needs of future space and terrestrial applications. MIRD-237
Methodological Framework MIRD-237 outlines a systematic methodology for converting quantitative imaging into absorbed dose distributions at voxel resolution. Key methodological components include: MIRD-237 is based on a proprietary chelator system